Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …

Background The differences in progression-free survival (PFS) and cancer-specific survival
(CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

OBJECTIVES: Clinical outcomes in older adults with metastatic renal cell carcinoma
(mRCC) are poorly understood, particularly in the era of targeted therapies. We characterize …

Background The current available evidence on the management of metastatic renal cell
cancer (mRCC) in real life is scarce in our environment. We present a summary of the …

Background For patients with metastatic renal cell carcinoma (mRCC), targeted therapies
have entered the market since 2006. The aims of this study were to evaluate the uptake and …

Objective To examine the patterns of care and outcomes for metastatic renal cell carcinoma
(mRCC) in A ustralia, where there are limited reimbursed treatment options. In particular, we …

Background Consistent with other data sets, our own institutional series suggests that
survival in patients aged≥ 75 years with metastatic renal cell carcinoma (mRCC) is inferior …

Background Advances in systemic targeted therapies afford treatment opportunities in
patients with metastatic renal cell carcinoma (RCC). Elderly patients with metastatic RCC …

Objective To assess the patterns and predictors of metastatic disease in renal cell carcinoma
(RCC) at the time of diagnosis in a contemporary series. Methods The Surveillance …